House appropriators add items to their list of nutritional product-related requests for the US Food and Drug Administration, repeat some and elaborate further on others but have comparatively little to say about the agency’s work on allowing the use of cannabinoids in dietary supplements.
The Appropriation Committee’s report accompanying legislation including the FDA’s fiscal year 2022 funding appears to signal that other than...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?